Compare Amphastar Pharmaceuticals Inc (AMPH) vs Direxion NASDAQ 100 Equal Weighted Index Shares (QQQE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Direxion NASDAQ 100 Equal Weighted Index Shares — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Direxion NASDAQ 100 Equal Weighted Index Shares trades at $122.36. The key difference: Direxion NASDAQ 100 Equal Weighted Index Shares is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | QQQE | |
|---|---|---|
Market Cap | $863.95M | — |
Sector | Health | Broad Market / Factor |
52-Week High | $30.81 | $122.72 |
52-Week Low | $16.87 | $96.06 |
Enterprise Value | $1.26B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
QQQE trades at $121.96, up 1.61% with strong bullish technical signals from moving averages. The equal-weighted Nasdaq-100 ETF offers diversified exposure to large-cap growth stocks, reducing concentration risk compared to market-cap weighted alternatives. Recent news highlights SpaceX's potential Nasdaq-100 inclusion as a catalyst for equal-weighted strategies.
The ETF's equal-weight approach provides defensive positioning amid tech concentration concerns, with recent outperformance driven by mid-tier growth and biotech exposure. Key risks include market volatility and tech sector sensitivity, while institutional interest grows due to balanced Nasdaq exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Direxion NASDAQ 100 Equal Weighted Index Shares
QQQE is an ETF that seeks to track the performance of the NASDAQ-100 Equal Weighted Index. Unlike traditional market-capitalization-weighted indexes, this fund assigns equal weight to each of the 100 non-financial companies in the NASDAQ-100 and rebalances quarterly. This equal-weighting scheme reduces concentration risk in the largest technology companies and increases the fund's exposure to smaller-cap and mid-cap companies within the index, providing a differentiated growth profile.
Read more on QQQE →
